logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10696693 B1

PDFFull Text
Date of Patent:
Jun. 30, 2020

Filed:

Nov. 16, 2015

Fused imidazole derivatives as tgf-beta inhibitors

Applicant:

Rigel Pharmaceuticals, Inc., South San Francisco, CA (US);

Inventors:

Rajinder Singh, Belmont, CA (US);

Todd Kinsella, Redwood City, CA (US);

Jiaxin Yu, Foster City, CA (US);

Marina Gelman, San Francisco, CA (US);

Ihab S. Darwish, San Carlos, CA (US);

Assignee:

Rigel Pharmaceuticals, Inc., South San Francisco, CA (US);

Attorney:

James J. Diehl

Primary Examiner:

Venkataraman Balasubramanian

Int. Cl.
CPC ...
C07D 498/04 (2006.01); C07D 487/04 (2006.01); C07D 519/00 (2006.01); A61K 31/424 (2006.01); A61K 31/428 (2006.01); A61K 31/498 (2006.01); A61P 19/02 (2006.01); A61K 31/416 (2006.01); A61K 31/4188 (2006.01); A61K 31/4365 (2006.01); A61K 31/437 (2006.01); A61K 31/4709 (2006.01); A61K 31/517 (2006.01); A61K 31/519 (2006.01); A61K 31/5377 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
C07D 519/00 (2013.01); A61K 31/416 (2013.01); A61K 31/4188 (2013.01); A61K 31/428 (2013.01); A61K 31/437 (2013.01); A61K 31/4365 (2013.01); A61K 31/4709 (2013.01); A61K 31/498 (2013.01); A61K 31/517 (2013.01); A61K 31/519 (2013.01); A61K 31/5377 (2013.01); A61K 45/06 (2013.01); A61P 19/02 (2018.01); C07D 487/04 (2013.01); C07D 498/04 (2013.01);
Abstract

Disclosed are imidazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure Formula (I) and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein A, Z, X, R, Rm, p and a are as described herein. In certain embodiments, a compound disclosed herein inhibits TGF-β, and can be used to treat disease by blocking TGF-β signaling.

Find Patent Forward Citations

Loading…